

**Daftar Pustaka**

- Abdelrahman A.E., Ibrahim H.M., Elsebai E.A., Ismail E.I., dan Elmessalamy W., 2018, ‘The clinicopathological significance of CD133 and SOX2 in astrocytic glioma’, *Cancer Biomarker*, 23 : 391-403. DOI 10.3233/CBM-181460
- Aghajani M., Mansoori B., Mohammadi A., Asdzadeh Z., dan Baradarab B., 2019, ‘New emerging roles of CD133 in cancer stem cell: signaling pathway and miRNA regulation’, *Cellular Physiology*. DOI: 10.1002/jcp.28824
- Allison K., 2012, ‘Molecular pathology of breast cancer : What a pathologist needs to know’, *American Journal of Clinical Pathology*, 138:770-780. DOI: 10.1309/AJCPIV9IQ1MRQMOO
- Behrooz A.B., Syahir A., dan Ahmad S., 2019, ‘CD133: beyond a cancer stem cell biomarker’, *Journal of Drug Targeting*, vol. 27 no.3 p.257-269. <https://doi.org/10.1080/1061186X.2018.1479756>
- Bellanger M., Zeinomar N., Tehranifar P., dan Terry M.B., 2018, ‘Are global breast cancer incidence and mortality patterns related to country specific economic development and prevention strategies?’, *Journal of Global Oncology*, American Society of Clinical Oncology.
- Bock C., Kuhn C., Ditsch N., Krebold R., Heublein S., Mayr D., Doisneau-Sixou S., dan Jeschke U., 2014, ‘Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events’, *J Cancer Res Clin Oncol* 140, 1873–1881. <https://doi.org/10.1007/s00432-014-1750-z>
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., dan Jemal A., 2018, ‘Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *Cancer Journal for Clinician*, 68 : 394-424
- Chen Y., Shi L., Zhang L., Li R., Liang J., Yu W., Sun L., Yang X., Wang Y., Zhang Y., dan Shang Y., 2008., ‘The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer’, *The Journal of Biological Chemistry*, 283 (26): 17969-17978. DOI 10.1074/jbc.M802917200
- Colditz G. dan Chia K.S., 2012, ‘invasive breast carcinoma: introduction and general features’ in Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., Van de Vijver M.J., (eds), *WHO Classification of Tumours of the Breast*, IARC: Lyon.
- Crabtree J.S. dan Miele L., 2018, ‘Breast cancer stem cells’, *Biomedicines*, 6 : 77. doi:10.3390/biomedicines6030077
- De Santis C.E., Ma J., Gaudet M.M., Newman L.A., Miller K.D., Sauer A.G., Jemal A., dan Siegel R.L., 2019, ‘Breast Cancer Statistics’, *CA Cancer J Clin*, 69 (6): 438 - 451. doi:10.3322/caac.21583

- Ding Q., Miyazaki Y., Tsukasa K., Matsubara S., Yoshimitsu M., dan Takao S., 2014., ‘CD133 facilitates epithelial-mesenchymal transition through interaction with ERK pathway in pancreatic cancer metastasis’, *Molecular Cancer*, 13: 15
- Ellis I.O., Collins L., Ichihara S., dan MacGrogan G., 2012, ‘Invasive carcinoma of no special type’, in Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., Van de Vijver M.J., (eds), *WHO Classification of Tumours of the Breast*, IARC: Lyon.
- Eroles P., Bosch A., Perez-Fidalgo J.A., dan Lluch A., 2012, ‘Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways’, *Cancer Treatment Reviews*, 38 : 698 – 707. doi:10.1016/j.ctrv.2011.11.005
- Fan L., Goss P.E., dan Strasser-Weippl K., 2015, ‘Current Status and Future Projections of Breast Cancer in Asia’, *Breast Care*, 10: 372 – 378. DOI: 10.1159/000441818
- Feng Y.X., Spezia M., Huang S., Yuan C., Zeng Z., Zhang L., Ji X., Liu W., Huang B., Luo W., Liu B., Lei Y., Du S., Vuppalapati A., Luu H.H., Haydon R.C., He T., dan Ren G., ‘Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis’, *Genes and Diseases*, 5: 77-106. <https://doi.org/10.1016/j.gendis.2018.05.001>
- Gao H., Teng C., Huang W., Peng J., dan Wang C., 2015, ‘SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF- $\alpha$  signaling’ , *International Journal of Molecular Sciences*, 16: 21643-21657. doi:10.3390/ijms160921643
- GLOBOCAN, 2018, International Agency for Research on Cancer, World Health Organization.
- Glumac P.M. dan Lebeau A.M., 2018, ‘The role of CD133 in cancer : a concise review’, *Clinical and Translational Medicine*, 7 : 18. <https://doi.org/10.1186/s40169-018-0198-1>
- Han L., Gao X., Gu X., Guo W., Ma M., Qi X., Cui M., Xie M., Bai Y., Peng C., dan Li X., 2017, ‘Prognostic significance of cancer stem cell marker CD133 expression in breast cancer’, *International Journal of Clinical Experimental Medicine*, 10(3): 4829-4837.
- Jang J., Song Y., Kim S., Kim J., dan Seo, H.R., 2017, ‘Potential mechanism of CD133 in cancer stem cells’, *Life Sciences*, 184: 25-29. <http://dx.doi.org/10.1016/j.lfs.2017.07.008>
- Jin X. dan Mu P., 2015, ‘Targeting breast cancer metastasis’, *Breast Cancer: Basic and Clinical Research*, 9 (S1) 23 – 34.
- Kazama S., Kishikawa J., Kiyomatsu T., Kawai K., Nozawa H., Ishihara S., dan Watanabe T., 2018, ‘Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesis’, *Asian Journal of Surgery*, 41(3), 274–278.
- Kementerian Kesehatan RI, 2016, ‘Kanker Payudara’, *Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI*, Oktober 2016.

Konishi H., Asano N., Imatani A., Kimura O., Kondo Y., Jin X., Kanno T., Hatta W., Ara N., Asanuma K., Koike T., dan Shimosegawa T., 2016, 'Notch1 directly induced CD133 expression in human diffuse type gastric cancers, *Oncotarget*, vol.7, no.35.

Kumar V., Abbas A.K. dan Aster J.C, 2015, Robbins and Cotran Pathologic Basis of Disease, ninth ed., Philadelphia : Elsevier, Chapter 7, p.306-310.

Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., dan Van de Vijver M.J., (eds), 2012, WHO Classification of Tumours of the Breast, IARC : Lyon.

Leis O., Eguiara A., Lopes-Arribillaga E., Alberdi M.J., Hernandez-Garcia S., Elorriaga K., Pandiella A., Rezola R., dan Martin A.G., 2012, 'SOX2 expression in breast tumours and activation in breast cancer stem cells', *Oncogene*, 31: 1354-1365. doi:10.1038/onc.2011.338

Lengerke C., Fehm T., Kurth R., Neubauer H., Scheble V., Muller F., Schneider F., Petersen K., Wallwiener D., Kanz L., Fend F., Perner S., Bareiss P.M., dan Staebler A., 2011, 'Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma', *Biomed Central Cancer*, 11 :42.

Li C., Li Y., Xing Y., Ca B., Yang F., Yang T., Ai Z., Wei Y., dan Jiang J., 2016, 'The interaction between cancer stem cell marker CD133 and Src protein promotes focal adhesion kinase (FAK) phosphorylation and cell migration', *The Journal of Biological Chemistry*, vol. 291, no.30, pp.15540-15550. DOI 10.1074/jbc.M115.712976

Li X., Xu Y., Chen Y., Chen S., Jia X., Sun T., Liu Y., Li X., Xiang R., dan Li N., 2013, 'SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/β-catenin signal network', *Cancer Letters*, <http://dx.doi.org/10.1016/j.canlet.2013.03>.

Li Z., 2013, 'CD133: a stem cell biomarker and beyond', *Experimental Hematology and Oncology*, 2 : 17.

Lida H., Suzuki M., Goitsuka R., dan Ueno H., 2012, 'Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2', *International Journal of Oncology*, 40: 71-79. DOI: 10.3892/ijo.2011.1207

Liou G., 2019, 'CD133 as a regulator of cancer metastasis through the cancer stem cells', *International Journal of Biochemistry and Cell Biology*, 106 : 1-7. <https://doi.org/10.1016/j.biocel.2018.10.013>

Liu K., Lin B., Zhao M., Yang X., Chen M., Gao A., Liu F., Que J., dan Lan X., 2013, 'The multiple roles for SOX2 in stem cell maintenance and tumorigenesis', *Cellular signalling*, Elsevier. <http://dx.doi.org/10.1016/j.cellsig.2013.02.013>

Liu P., Tang H., Song C., Wang J., Chen B., Huang X., Pei X., dan Liu L., 2018, 'SOX2 promotes cell proliferation and metastasis in triple negative breast cancer', *Frontiers in Pharmacology*. doi: 10.3389/fphar.2018.00942

Liu X., Qiao B., Zhao T., Hu F., Lam A.K., dan Tao Q., 2018, ‘SOX2 promotes tumor aggressiveness and epithelial-mesenchymal transition in tongue squamous cell carcinoma’ , *International Journal of Molecular Medicine*, 42: 1418-1426. doi: 10.3892/ijmm.2018.3742

Mak A.B., Nixon A.M.L., Kittanakom S., Stewart J.M., Chen G.I., Curak J., Gingras A., Mazitschek R., Neel B.G., Stagljar I., dan Moffat J., 2012, ‘Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation’ , *Cell Rep*, 2 (4): 951-963. doi:10.1016/j.celrep.2012.09.016

Mansouri S., Nejad R., Karabork M., Ekinci C., Solaroglu I., Aldape K.D, dan Zadeh G., 2016, ‘SOX2 : regulation of expression and contribution to brain tumors’ , *CNS Oncology*, 5 (3) : 159-173

Mego M., Mani S.A., dan Cristofanilli M., 2010, ‘Molecular mechanisms of metastasis in breast cancer – clinical applications’ , *Natural Reviews Clinical Oncology*, 7 : 693-701. doi:10.1038/nrclinonc.2010.171

Mehta G.A., Khanna P., dan Gatza M.L., 2019, ‘Emerging role of SOX2 proteins in breast cancer development and maintenance’ , *Journal of Mammary Gland Biology and Neoplasia*, Springer. <https://doi.org/10.1007/s10911-019-09430-6>

Neumann J., Bahr F., Horst D., Kriegl L., Engel J., Mejias-Luque R., Gerhard M., Kirchner T., dan Jung A., 2011, ‘SOX2 expression correlates with lymph-node metastasis and distant spread in right-sided colon cancer’ , *Biomedicine Central Cancer*, 11: 518

Nomura A., Banerjee S., Chugh R., Dudeja V., Yamamoto M., Vickers S.M., dan Saluja A.K., 2015, ‘CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer’ , *Oncotarget*, vol.6, no.10.

Park E.K., Lee J.C., Park J.W., Bang S.Y., Yi S.A., Kim B.K., Park J.H., Kwon S.H., You J.S., Nam S.W., Cho E.J., dan Han J.W., 2015, ‘Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53’ , *Cell Death Dis*. 6, e1964.

Prieto-Villa M., Takahashi R., Usuba W., Kohama I., dan Ochiya T., 2017, ‘Drug resistance driven by cancer stem cells and their niche’ , *International Journal of Molecular Sciences*, 18, 2574. doi:10.3390/ijms18122574

Putra P.K.B.S., Sumadi I.W.J., Sriwidjani N.P., dan Setiawan I.G.B., 2020, ‘Karakteristik Klinikopatologik Pasien Kanker Payudara dengan Metastasis Tulang di RSUP Sanglah pada tahun 2014 – 2018, *e-CliniC*, 8 (1): 146 - 151.

Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V., Fox S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Richardson A.L., Schnitt S.J., Schmitt F.C., Tan P., Tse G.M., Badve S., dan Ellis I.O., 2010, ‘Breast cancer prognostic classification in the molecular era : the role of histological grade’ , *Breast Cancer Research*, 12 : 207.

Ren Z., Zhang C., dan Ji T., 2016, ‘Expression of SOX2 in oral squamous cell carcinoma and the association with lymph node metastasis (review)’ , *oncology letter*, 11: 1973-1979. DOI: 10.3892/ol.2016.4207

Rodriguez-Pinilla S.M., Sarrio D., Moreno-Bueno G., Rodriguez-Gil Y., Martinez M.A., Hernandez L., Hardisson D., Reis-Filho J.S., dan Palacios J., 2007, 'SOX2: a possible driver of the basal-like phenotype in sporadic breast cancer', *Modern Pathology*, 20 : 474-481. doi:10.1038/modpathol.3800760

Saigusa S., Tanaka K., Toiyama Y., Yokoe T., Okugawa Y., Ioue Y., Miki C., dan Kusunoki M., 2009, 'Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemotherapy', *Annals of Surgical Oncology*, 16 ; 3488-3498. DOI 10.1245/s10434-009-0617-z

Scully O.J., Bay B., Yip G., dan Yu Y., 2012., 'Breast cancer metastasis', *Cancer Genomics and Proteomics*, 9: 311-320.

Shah R., Rosso K., dan Nathanson S.D., 2014, 'Pathogenesis, prevention, diagnosis and treatment of breast cancer', *World Journal of Clinical Oncology*, 5 (3): 283-298. DOI: 10.5306/wjco.v5.i3.283

Sin W.C. dan Lim C.L., 2017, 'Breast cancer stem cells – from origins to targeted therapy', *Stem Cell Investigation*, 4: 96. <http://dx.doi.org/10.21037/sci.2017.11.03>

Sinn H. dan Kreipe H., 2013, 'A brief overview of the WHO classification of breast tumours, 4th edition, focusing on issues and updates from 3rd edition', *Breast Care*, 8: 149-154. DOI: 10.1159/000350774

Sopik V. dan Narod S.A., 2018, 'The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer', *Breast Cancer Research and Treatment*, 170; 647 – 656. <https://doi.org/10.1007/s10549-018-4796-9>

Takebe N., Warren R.Q., dan Ivy S.P, 2011, 'Breast cancer growth and metastasis : interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition', *Breast Cancer Research*, 13 : 211

Toss A. dan Cristofanilli M., 2015, 'Molecular characterization and targeted therapeutic approaches in breast cancer', *Breast Cancer Research*, 17: 60. DOI 10.1186/s13058-015-0560-9

Tume L., Paco K., Ubidia-Incio R., dan Moya J., 2016., 'CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy', *Gaceta Mexicana De Oncologia*, 15(1): 22-30. <http://dx.doi.org/10.1016/j.gamo.2016.01.003>

Verwey M., Joubert A.M., Visagie M.H., dan Theron A.E., 2016, 'Chemoresistance in breast cancer stem cells', *Biomedical Research*, 27 (1) : 16-23

Wang H. dan Xie J., 2018, 'The role of SOX2 in angiogenesis in breast cancer', *International Journal of Clinical Experimental Pathology*, 11(5): 2805-2810.

Wu Y. dan Wu P.Y., 2009., 'CD133 as a marker for cancer stem cells: progresses and concerns', *Stem Cells and Development*, Vol.18, no.8. DOI: 10.1089/scd.2008.0338

Xiao Z-Y., Chen X-J., Pan Q., Yang Q-Z., dan Li K-Z., 2018, 'Expression of Nestin, CD133 and SOX2 in Meningiomas', *Turk Neurosurg*, 28 (6): 910 – 914. DOI: 10.5137/1019-5149.JTN.21234-17.2

Zhao P., Lu Y., Jiang X., dan Li X., 2011, ‘Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma’, *Cancer Science*, vol.102, no.5, pp.1107-1111. doi: 10.1111/j.1349-7006.2011.01894.x

Zhao W., Qin Y., Wu X., Wu S., Zhao Y., dan Tao Y., 2018, ‘Correlation of CD133, E-cadherin, and  $\beta$ -catenin with metastasis and prognosis in esophageal squamous cell carcinoma’, *International Journal of Clinical Experimental Medicine*, 11(9): 8583-9592.